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E-mail address: s.henson@ucl.ac.uk (S.M. Henson)The dysregulated immune response to CMV constitutes a major force driving T cell immunosenescence
and growing evidence suggests that it is not a benign virus in old age. We show here that the PD-1/L path-
way deﬁnes a reversible defect in CMV speciﬁc CD8+ T cell proliferative responses in both young and old
individuals. More speciﬁcally, highly differentiated CD45RA+CD27 CMV-speciﬁc CD8+ T cells exhibit a
proliferative deﬁcit compared their central and effector memory counterparts, which is reversed follow-
ing PD-L blockade. However, we also report that HLA-B⁄07/TPR speciﬁc CD8+ T cells express higher levels
of PD-1 than HLA-A⁄02/NLV speciﬁc cells and HLA-A⁄02 individuals show a higher proliferative response
to PD-L blockade, than HLA-B⁄07 individuals, which we postulate may be due to the differing functional
avidities for these two CMV-speciﬁc CD8+ T cells populations. Nevertheless data presented here demon-
strate that CMV-speciﬁc CD8+ T cells can be functionally enhanced by perturbation of the PD-1/L signal-
ling pathway, whose manipulation may provide a therapeutic modality to combat age-associated
immune decline.
 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights
reserved.1. Introduction
Ageing is accompanied by a progressive, multidimensional,
physiological degeneration, with immune system alterations play-
ing a key role regulating these age-related declines [1]. Age-associ-
ated deleterious changes have been best characterised amongst the
adaptive immune system, particularly among T cells, which exhibit
profound age-associated alterations. Indeed, though peripheral T
cell numbers do not diminish with age, the peripheral T cell pool
undergoes a striking age-related remodelling, which is much more
profoundly observed amongst the CD8+ T cell compartment than
the CD4+ [2]. The proportion of naive CD8+ T cells (and thus the
T cell receptor (TCR) repertoire) exhibit a dramatic age-associated
diminution accompanied by a large accumulation of highly differ-
entiated T cells [3].
Such immune alterations typically associated with advanced
age can also be observed in relatively young individuals who have
been subjected to a high antigenic load, such as those with Human
Immunodeﬁciency Virus (HIV) [4], cancer [5], and auto-immune
diseases [6]. Among developed nations, the ubiquitous and rela-
tively innocuous herpes virus Cytomegalovirus (CMV) appears to
act as the dominant chronic stressor, and is associated with many
of the same phenotypic and functional alterations to T cell immu-
nity seen with aging. Collectively these changes, in addition ton Society for Histocompatibility an
.CMV infection, are known as the Immune Risk Phenotype (IRP),
that have been suggested as biomarkers of immune system ageing
[7,8]. The signiﬁcance of CMV infection in health outcomes of el-
derly individuals is further highlighted by its association with del-
eterious responses to inﬂuenza vaccination [9], and Epstein-Barr
Virus (EBV) infections [10]. The case for CMV driving immunose-
nescence has been further strengthened by the recent ﬁnding that
CMV seropositivity acts as an independent risk factor for prema-
ture mortality amongst American adults [11].
In direct contrast to the T cell response observed towards most
other pathogens, the magnitude of the CMV immune response
undergoes a progressive long term expansion with age [2,12] that
can dominate the T cell compartment of elderly donors [12–14].
This expansion of increasingly clonal, dysfunctional and differenti-
ated CMV speciﬁc CD8+ T cells may out-compete other T cell
populations for immunological space, resulting in loss of immuno-
logical memory to previously controlled pathogens and further
constrictions in the TCR repertoire [15]. Indeed, amongst aged indi-
viduals, repertoire shrinkage of clonally expanded CD8+ T cells is
predictive of reduced lifespan [16]. Furthermore, humoural anti-
CMV responses also signiﬁcantly intensify with advancing age,
whose magnitude correlates with co-morbidity and functional de-
cline [17]. Thus, the increasing weight of immune resources dedi-
cated to the control of CMV may signiﬁcantly impair immune
responses amongst the aged and drive age-related immune decline.
It has been suggested that lifelong persistent CMV reactivation
may drive clonal exhaustion of the most efﬁcient and speciﬁc Td Immunogenetics. Published by Elsevier Inc. All rights reserved.
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to control virus infection [15]. Exhausted T cells are subject to com-
plex layers of negative regulation by signalling through multiple
inhibitory receptors that inhibit functional responses [18]. The
inhibitory receptor, programmed cell death 1 (PD-1) has been
shown to be the best characterised inhibitory receptor in the con-
text of chronic infection and has a major role in regulating T cell
exhaustion [18,19]. An important ﬁnding is that blockade of the
PD-1 pathway has been used to reinvigorate antigen-speciﬁc T cell
responses in LCMV-infected mice [19] and in humans reinvigorates
HIV [20–22], HBV [23] and HCV [24,25] speciﬁc CD8+ T cells. We
show here that manipulation of the PD-1/L axis reinvigorates
CMV speciﬁc CD8+ T cell function in both young and old individu-
als. However our ﬁndings also indicate that HLA-A⁄02 and B⁄07
CMV-speciﬁc T cells display differing levels of PD-1 expression
and proliferative response to aPD-L1/2 blockade.2. Materials and methods
2.1. Blood sample collection and isolation
Heparinised peripheral blood samples were taken from healthy
volunteers (Age range: 20–92). All samples were obtained in accor-
dance with the ethical committee of Royal Free and University Col-
lege Medical School. Peripheral blood mononuclear cells (PBMC)
were isolated using Ficoll hypaque (Amersham Biosciences) and
experiments performed immediately thereafter.Fig. 1. CMV causes the accumulation of highly differentiated CD8+ T cells. (A) Representa
negative (left panel) or pentamer-positive (right panel) T cells. (B) Cumulative data fro
negative (black symbols) and CMV-speciﬁc CD8+ T cells (grey symbols). Horizontal lines d
Representative examples of PD-1 staining on CD45RA/CD27 CMV pentamer positive CD8
CD8+ T cells subsets. Horizontal lines depict mean values. P values were calculated usin2.2. Identiﬁcation of CMV responding donors
PBMCs were incubated with CMV-infected cell lysate prepared
by infecting human embryonic lung ﬁbroblasts with the Towne
strain of CMV (European Collection of Animal Cell Cultures) at a
multiplicity of infection of 2. After 5 d, the infected cells were lysed
by repeated freeze–thaw cycles. PBMC were left unstimulated or
stimulated with CMV lysate for 15 h at 37 C in a humidiﬁed CO2
atmosphere, with 5 lg/ml Brefeldin A (Sigma–Aldrich) added after
2 h. PBMCs were then stained with anti-CD4 and anti-IFNc, with
donors being considered CMV seropositive when showing a posi-
tive IFNc response [12], with a concordance between seropositivity
and a positive IFN-c response in the blood [12].2.3. Flow cytometric analysis
Up to ﬁve colour ﬂow cytometric analysis was performed using
the following antibodies: FITC conjugated Ki67 (B56), CD45RA APC
(MEM-56), CD4 PerCP (SK7) CD8 PerCP (SK1), IFNc APC (B27),
CD27 FITC (M-T271), CD45RA PE-Cy7 (L48), all from BD Biosci-
ences. Additionally, PE and APC- labelled HLA-A2 and HLA-B7 re-
stricted pentamers were used to identify CMV positive
individuals who may have speciﬁc CD8+ T cells directed against
the CMV tetramers NLVPVMTV and TPRVTGGGAM, respectively
(ProImmune, Oxford, UK). PD-1 expression was analysed using
clone EH12-2H7-PE, kind gift from Dr. G. Freeman, Dana-Farber
Cancer Institute, Boston. The PMBCs were stimulated with 0.5 lg/tive density plots showing the CD45RA/CD27 phenotypic proﬁles of CD8+ pentamer-
m 13 young and old donors showing CD45RA and CD27 expression on pentamer
epict mean values. P values were calculated using a repeated measures ANOVA. (C)
+ T cells. (D) Graph showing the MFI of PD-1 expression on CMV pentamer positive
g a repeated measures ANOVA.
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sion as described previously [26,27].2.4. Effects of antibody blockade on PD-1 expression and proliferative
responses of CD8+ NLV/TPR speciﬁc T cells
Samples were blocked using 10 lg/ml PD-L1 (29F.2A3) and PD-
L2 (24F) kind gift from Dr. G. Freeman, Dana-Farber Cancer Insti-
tute, Boston or their relevant isotype control IgG2b (MPC-11) from
Abcam. One lg/ml IFNaR block (Calbiochem) or IgG2a isotype con-
trol (Abcam) were also used. All blocking antibodies were azide
free.
PBMCs were stimulated with 0.2 lg/ml TPRVTGGGA or NLVPM-
VATV peptide (ProImmune) for 3 d in the presence of inhibitory
receptor blockade or relevant isotype control before staining with
Ki67, a nuclear antigen associated with proliferation, to determine
CMV speciﬁc CD8+ T cell proliferation. The effect of cytokine on PD-
1 expression was determined by stimulating PBMCs in duplicate
with 0.5 lg/ml plate coated anti-CD3 for 24 h in the presence of
500 U/ml IFNa (PeproTech EC), or IFNaR block prior to ﬂow cyto-
metric analysis of PD-1 expression, as detailed above.2.5. Statistical analysis
Data analysis was performed using GraphPad Prism (GraphPad
Software) with statistical signiﬁcance being evaluated by either an
unpaired or paired Student’s t-test or a repeated measures ANOVA.
P values of less than 0.05 were considered statistically signiﬁcant.Fig. 2. PD-1 expression is higher in CMV positive individuals driven by IFNa. (A) Represe
old CMV negative and positive donors. (B) Graph showing the expression levels of PD-1
old donors. Horizontal lines depict mean values. P values were calculated using a Stude
Horizontal lines depict mean values, and P values were calculated using the Student’s t3. Results
3.1. CMV causes the accumulation of highly differentiated CD8+ T cells
expressing high levels of PD-1
It is known that highly differentiated CD8+ T cells accumulate
during ageing but what is unclear is the contribution of CMV spe-
ciﬁc T cells to this build-up of highly differentiated CD8+ T cells.
Therefore the CMVpp65-speciﬁc population, deﬁned by the HLA-
A⁄02 and B⁄07 peptides, in both young and old individuals were
analysed for the expression of CD45RA and CD27, markers com-
monly used to determine T cell phenotype (Fig. 1A). CMV-speciﬁc
T cells showed signiﬁcantly (P < 0.05) higher levels of effector
memory like (CD45RACD27) and highly differentiated EMRA
(CD45RA+CD27) T cells compared to the CD8+ T cell pool (Fig. 1B).
It has been suggested that lifelong persistent CMV reactivation
may drive clonal exhaustion of the most efﬁcient and speciﬁc T
cells so that an increased number of suboptimal cells are required
to control virus infection [15]. Therefore, reinvigorating CMV-spe-
ciﬁc CD8+ T cell functions could allow better control of CMV infec-
tion and thus impair memory inﬂation and the development of
immunosenescence. A potential mechanism for regulating this
dysfunction could be though inhibitory receptor signalling. PD-1
has been the best characterised inhibitory receptor in the context
of chronic viral infections [19–22]. We and others have shown
PD-1 to be differentially expressed on global CD8+ T cells with
the highest level of expression found on the mid-differentiated T
cells [28,29]. The expression of PD-1 on CMV pentamer positive T
cells was found to display a very similar pattern (Fig. 1C), with
the highest levels of PD-1 being expressed on CD45RACD27+ntative histograms showing the expression of PD-1 on CD8+ T cells from young and
on CMV negative (black symbols) and CMV positive (grey symbols) from young and
nt’s t-test. (C) Graph showing the effect of IFNa on PD-1 expression in CD8 T cells.
-test.
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shown that there is no age-related increase in PD-1 expression
[30–32] However we show here that PD-1 is up-regulated when
young and old donors are stratiﬁed according to their CMV status,
with both young and old CMV positive individuals displaying sig-
niﬁcantly higher (P < 0.005, P < 0.01 respectively) expression of
PD-1 upon CD8+ T cells when compared to CMV negative individ-
uals (Fig. 2A and B).
We then sort to determine the cause of this elevated PD-1
expression in CMV positive individuals. We chose to investigated
the effect of IFNa, which is secreted at high levels in response to
CMV and, by virtue of its ability to induce co-stimulatory receptor
loss and inhibit telomerase activity, has been suggested to be the
factor driving accelerated T cell differentiation in CMV infected
individuals [12,33] We found the expression of PD-1 on CD8+ T
cells in response to overnight stimulation with IFNa to be signiﬁ-
cantly increased (P < 0.005; Fig. 2C). Furthermore when a blocking
antibody against IFNaR was added the amount of PD-1 decreased
signiﬁcantly (P < 0.0005; Fig. 2C).3.2. PD-1/L blockade augments the proliferative responses of CMV
speciﬁc CD8+ T cells
We show here that PBMCs when stimulated for 3 d with 0.2 lg/
ml CMV peptide in the presence of an anti-PD-L1/2 blockingFig. 3. Blocking PD-1/L interactions augments the proliferative responses of CMV speciﬁ
Ki67 staining following 3 d stimulation with CMV peptides in the presence of aPD-L1/2 b
blockade compared to the isotype control. (C) Representative dot plots showing the chan
in the presence of PD-L blockade or isotype control. (D) Cumulative data illustrating the ef
all P values were calculated using a paired Student’s t-test.antibody signiﬁcantly increased their CD8+ T cell proliferative re-
sponse from both young and old individuals (P < 0.01, P < 0.05
respectively), determined by Ki67 expression when compared with
its relevant isotype control (IgG2b young mean, 30.1%; PD-L young
mean, 62.6%; IgG2b old mean, 20.6%; PD-L old mean, 47.7%; Fig. 3A
and B). This increase in CMV-speciﬁc CD8+ T cell proliferative re-
sponse following PD-L blockade was not accompanied by a propor-
tionate increase in the percentage of CD8+ T cells binding the CMV
tetramer in either young or old donors (IgG2b young mean, 1.1%;
PD-L young mean, 1.4%; IgG2b old mean, 4.9%; PD-L old mean,
5.7%; Fig. 3C and D).3.3. HLA-A⁄02 and B⁄07 individuals show differing levels of PD-1
expression and respond differently to PD-L blockade
An intriguing observation was that HLA-A⁄02 and B⁄07 individ-
uals display differing levels of PD-1, with A⁄02 donors expressing
signiﬁcantly less PD-1 on their CMV-speciﬁc CD8+ T cells
(P < 0.05) than B⁄07 donors (Fig. 4A). This effect was not dependent
on the total percentage of CMV+CD8+ T cells (Fig. 4B) or differenti-
ation status of NLV-speciﬁc of TPR-speciﬁc cells (Fig. 4C), as no sig-
niﬁcant difference in either was found. This altered level of PD-1
expression between HLA-A⁄02 and B⁄07 donors was found to
translate to an altered Ki67 proliferative response, with A⁄02 do-
nors showing signiﬁcantly higher levels of proliferation comparedc CD8+ T cells amongst both young and old donors. (A) Representative examples of
locking antibody or isotype control. (B) Pooled data showing the effect of aPD-L1/2
ge in proportion of CMV-speciﬁc CD8+ T cells following 3 d CMV peptide stimulation
fect of aPD-L1/2 blockade on the proportion of CD8+ T cells that are CMV speciﬁc. For
Fig. 4. Expression of PD-1 is higher on CMV-speciﬁc B⁄07 individuals. (A).
Comparison of the expression levels of PD-1 on HLA-A⁄02 or B⁄07 CMV-speciﬁc
populations. (B). Graph showing no difference in the percentage of total HLA-A⁄02
or B⁄07 CMV-speciﬁc CD8+ T cells. (C). Data illustrating that there was no difference
in the CD45RA/CD27 phenotypic proﬁles of HLA-A⁄02 or B⁄07 CMV-speciﬁc CD8+ T
cells. For all graphs horizontal bars depict mean values and P values were calculated
using a Student’s t-test.
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Also of note was the highest fold change in both A⁄02 and B⁄07
was found to be in the highly differentiated CD45RA+CD27 CD8+
T cells, the CD45RA re-expressing memory subset exhibits a prolif-
erative deﬁciency, relative to their central and effector memory
counterparts, that was found to be reversible upon PD-L blockade
(Fig. 5B).
4. Discussion
CMV immunosurveillance is widely considered to be main-
tained even in the very old [34]. However, CMV may sub-clinically
reactivate with increasing frequency with age [35]. Additionally,
intense immune responses to extracellular CMV in very old sub-
jects have recently been observed, whose magnitude is associated
with co-morbidity and functional decline [17]. Thus, the increased
frequency and magnitude of CMV reactivation in advanced age
could result in direct or indirect CMV related pathology, which
may signiﬁcantly contribute towards their impaired health status.
It has been suggested that undiagnosed occult CMV pneumonitis
followed by bacterial pneumonia may constitute a common prox-
imate cause of death in the old [3]. Furthermore CMV has been
implicated in the loss of response to vaccines in older people [9].
Infection with CMV causes plasmacytoid dendritic cells to se-
crete high levels of IFNa [12], which can drive T cell differentiation
and may signiﬁcantly contribute towards the CMV associatedglobal differentiation of the T cell pool [36,37]. Furthermore we
show here that IFNa upregulates PD-1, which may account for
the T cell pool of CMV positive donors expressing enhanced levels
of PD-1 compared with their CMV negative counterparts. Blocking
studies revealed that IFNa alone contributes half the PD-1 expres-
sion induced by an anti-CD3 stimulus, highlighting its functional
signiﬁcance.
PD-1 has been shown to play a role in the dysregulation of CD8+
T cell responses to CMV [20,38], so we sort to investigate whether
the manipulation of the PD-1/L axis could functionally reinvigorate
CMV-speciﬁc CD8+ T cell, in particular their defective proliferative
response which is exacerbated by advancing age [10,12,13]. We
demonstrate here that CMV speciﬁc CD8+ T cell proliferative re-
sponses could be enhanced by blocking PD-1/L interactions in both
young and old individuals; with the highly differentiated CD45RA+-
CD27 CD8+ T cells showing the largest increase in proliferative re-
sponse compared to the less differentiated subsets. This may seem
counter intuitive as the CD45RA+CD27 subset does not express
high levels of PD-1. However PD-1 is transiently up-regulated in
activated T cells [39] and the low levels of PD-1 seen in this subset
may represent their inability to proliferate. When combined with
the changes to cell signalling in this subset it may cause the
CD45RA+CD27 T cells to be more susceptible to PD-1/L receptor
blockade. However the contribution of other inhibitory receptors
cannot be discounted, for the number and intensity of inhibitor
receptor expression has been correlated with functional exhaus-
tion [18]. One inhibitor receptor that has been shown to be highly
expressed on CD45RA+CD27 T cells is KLRG1 [30,40], whilst the
expression of KLRG1 has not been demonstrated to be strongly
associated with PD-1 co-expression during exhaustion 18, expres-
sion of KLRG1 was found on a signiﬁcant fraction of exhausted
CD8+ T cells [18,41]. As KLRG1 is up-regulation by repetitive anti-
gen stimulation, it is possible that its expression does not reﬂect T
cell exhaustion but rather ongoing antigen recognition, which is
thought to be the prerequisite for the development of CD8+ T cell
exhaustion [41,42].
We also found that the increased proliferative response of CMV-
speciﬁc CD8+ T cells following PD-L blockade was not accompanied
by a proportional increase in the response size. This, nevertheless,
concurs with PD-1 blocking studies performed in a murine LCMV
model [19], suggesting that proliferation is accompanied by con-
siderable cell death. This death may be analogous to the contrac-
tion phase of effector cell responses, which occurs following
antigen clearance in acute infections. Alternatively, PD-L blockade
may drive the selective expansion of less exhausted cells over their
more exhausted counterparts, which are driven further along the
exhaustion spectrum to death [43].
One surprising ﬁnding was that HLA-B⁄07/TPR speciﬁc CD8+ T
cells expressed higher levels of PD-1 than HLA-A⁄02/NLV speciﬁc
cells with no difference in the CD45RA/CD27 phenotypic proﬁles
of the CMV-speciﬁc CD8+ T cells. However there was a difference
in the proliferative response to PD-L blockade, with HLA-B⁄07 indi-
viduals showing less proliferation despite expressing more PD-1.
We would like to speculate here that this may be due to the differ-
ing functional avidities for the two CMV-speciﬁc CD8+ T cell popu-
lations. It has been reported that different HLA-types may equate
with different T cell functional avidity for antigen during chronic
viral infection [44,45]. CMV-speciﬁc CD8+ T cells with high avidity
expressed all effector functions upon activation ex-vivo compared
with low avidity CD8+ T cells, which exhibited no ex-vivo cytotox-
icity and secreted minimal IFN-c [46]. Although CMV disease is
rare in immune-competent individuals, HLA type can still inﬂuence
the T cell response of these individuals [47,48]. Indeed, a minimal
number of CD8+ CMV-speciﬁc T cells have been estimated to be
needed for protection against CMV reactivation during organ trans-
plantations [49,50]. These numbers seem to differ on the basis of
Fig. 5. Blocking PD-1/PD-L interactions augments HLA-A⁄02 speciﬁc responses by a greater magnitude than that of HLA-B⁄07. (A) Representative dot plots showing Ki67
staining on NLV+ CD8+ T cell subsets following 3 d stimulation in the presence of PD-L blockade or isotype control. (B) Cumulative data comparing the effects of PD-L receptor
blockade on the fold increase of the proportion of NLV A2 and TPR B7 CMV speciﬁc CD8+ T cells subsets expressing Ki67 deﬁned by CD45RA/CD27. Horizontal bars depict
mean values and P values were calculated using a repeated measures ANOVA.
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conferred protection from CMV reactivation with signiﬁcantly low-
er cell numbers than HLA-A⁄0201-speciﬁc CD8+ T cells [51]. Inter-
estingly, individuals having both HLA-A⁄02 and HLA-B⁄07 alleles
show preferential and dominant T cell numbers speciﬁc for the
TPR epitope of CMVpp65 over the NLV epitope [48]. Furthermore
these TPR speciﬁc T cells demonstrate preferential expansion over
A2 NLV-speciﬁc T cells taken from the same individual [48]. It is
therefore possible that inhibitory receptor blocking may preferen-
tially beneﬁt NLV-speciﬁc A2 restricted cells as their intrinsic re-
duced propensity to activate renders them susceptible to
inhibition, whilst highly avid cells, which have a strong activation
response are less likely to be inhibited by signalling through PD-1.
Why the more avid cells expressing higher levels of PD-1 should
be less susceptible to PD-1/L may be squared by the ﬁnding that
two subpopulations of virus speciﬁc CD8+ T cells have been identi-
ﬁed in both mouse LCMV and human HCV infections: a more ter-
minally differentiated PD-1hi subset, that responds poorly to PD-
1 blockade and a less differentiated more functional PD-1int popu-
lation that responds well to blockade [53,54]. However it should be
noted that in our study we were unable to distinguish PD-1int/hi
CD8+ T cells. The inability of PD-1hi virus-speciﬁc CD8+ T cells to re-
spond to PD-L1 blockade may reﬂect the expression of additional
inhibitory receptors on these highly exhausted cells [18]. The
behaviour of PD-1int and PD-1hi populations of CD8+ T cells speciﬁcfor poorly controlled persistent viral infections such as LCMV, HCV
and HIV may nevertheless, not be applicable to the well-controlled
latent CMV infection. Indeed, an HBV study, reported that the more
exhausted intrahepatic speciﬁc CD8+ T cells, expressing higher PD-
1 levels, responded more effectively than their less exhausted, low-
er PD-1 expressing, circulating counterparts [55]. In contrast,
Nakamoto et al. [54], documented opposing results; however in
this case, the disease status of the subjects was much more ad-
vanced. Furthermore, differing PD-1 expression levels may engage
distinct intracellular targets [56]. The blockade of PD-L on ex-
hausted PD-1int LCMV and HCV speciﬁc exhausted CD8+ T cells,
but not their PD-1hi counterparts, restored effector functions
[53,57], while the engagement of PD-1 on resting naïve T cells,
which express barely detectable levels of PD-1, effectively inhibits
T cell activation [56]. This suggests that rather than increased PD-1
expression correlating with greater signalling, differing PD-1
expression levels may engage distinct pathways [56]. For example,
PD-1 binds the SH2 domain-containing protein tyrosine phospha-
tases SHP-1 and SHP-2 in naïve T cells, but in exhausted cells the
very high levels of PD-1 expression can recruit additional signalling
molecules [56].
Regardless of TPR/NLV differences the highly differentiated
CD45RA+CD27 CD8+ T cells, which accumulate both with age
and CMV infection showed the highest fold change increase in pro-
liferative response compared to the less differentiated subsets with
308 R. Macaulay et al. / Human Immunology 74 (2013) 302–309PD-1/L blockade. PD-L blockade was shown to induce an increased
functionality without augmenting cell numbers which may be ben-
eﬁcial in the context of ageing where the large numbers of CMV-
speciﬁc CD8+ T cells are considered a signiﬁcant burden upon the
immune system of the aged [3].Authorship
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